Constellation Brands, Inc. · STZ · FY2027 Q1 · Calendar Q2 2026

Constellation Brands Beats on Q1 FY27 Beer Strength, Holds Guidance Amid Macro Uncertainty

Constellation Brands delivered a Q1 FY27 beat driven by beer shipment strength and cost discipline, but the market focused on management's refusal to raise guidance despite favorable Q2/Q3 comparisons. The company faces a tension between strong brand fundamentals and near-term margin pressure from elevated marketing spend (over 10% of net sales in Q2/Q3) and SG&A headwinds tied to the Veracruz brewery ramp. With the stock trading at $130.38 versus a consensus target of $165.20, the market is pricing in meaningful uncertainty around consumer health, particularly within the Hispanic demographic that anchors STZ's core customer base.

Reported After market closeNYSEConsumer Defensive $22.50B market cap
100quality score

Company context

Snapshot as of publication

Constellation Brands, Inc., together with its subsidiaries, produces, imports, markets, and sells beer, wine, and spirits in the United States, Canada, Mexico, New Zealand, and Italy. The company offers beer under the Corona Extra, Corona Familiar, Corona Hard Seltzer, Corona Light, Corona Non-Alcoholic, Corona Premier, Corona Refresca, Modelo Especial, Modelo Chelada, Modelo Negra, Modelo Oro, Victoria, Vicky Chamoy, and Pacifico brands. It also offers wine under the Cook’s California Champagne, Kim Crawford, Meiomi, Mount Veeder, Ruffino, SIMI, My Favorite Neighbor, Robert Mondavi Winery, Schrader, and The Prisoner Wine Company brands; and spirits under the Casa Noble, Copper & Kings, High West, Mi CAMPO, Nelson’s Green Brier, and SVEDKA brands. The company provides its products to wholesale distributors, retailers, on-premise locations, and state alcohol beverage control agencies. Constellation Brands, Inc. was founded in 1945 and is based in Rochester, New York.

Earnings scorecard

Reported versus consensus
Reported EPS $3.43 Consensus $3
EPS surprise +6.5% Reported versus consensus
Reported revenue $2.43B Consensus $2.39B
Revenue surprise +1.9% Reported versus consensus

Earnings History

Estimate Beat Miss Match
STZ REVENUE earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q4 '24 estimate $2B Q4 '24 actual $2B, beat Q1 '25 estimate $3B Q1 '25 actual $3B, miss Q2 '25 estimate $3B Q2 '25 actual $3B, miss Q1 '26 estimate $3B Q1 '26 actual $3B, miss Q2 '26 estimate $2B Q2 '26 actual $2B, beat Q3 '26 estimate $2B Q3 '26 actual $2B, beat Q4 '26 estimate $2B Q4 '26 actual $2B, beat Q1 '27 estimate $2B Q1 '27 actual $2B, beat Q2 '27 estimate $3B Q3 '27 estimate $2B Q4 '27 estimate $2B Q1 '28 estimate $2B
Show 1 more >

Analyst Consensus ?

ConsensusBuy46 ratings
Bullish2554.3%
Neutral2043.5%
Bearish12.2%

Analyst 52W Price Targets

$130.38Current
$132Low
$231.93Average
$335High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Barclays Equal Weight Equal WeightMaintainJul 21, 2026
Roth Capital Buy BuyMaintainJul 2, 2026
RBC Capital Outperform OutperformMaintainJul 2, 2026
Needham Buy BuyMaintainJul 2, 2026
Morgan Stanley Equal Weight Equal WeightMaintainJul 2, 2026
JP Morgan Neutral NeutralMaintainJul 2, 2026
Deutsche Bank Hold HoldMaintainJul 2, 2026
BMO Capital Outperform OutperformMaintainJul 2, 2026
Show 38 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $130.38. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
BarclaysAnalyst unavailable$132$134.36 +1.2%Jul 21, 2026
Deutsche BankSteve Powers$150$138.34 +15.0%Jul 2, 2026
Morgan StanleyDara Mohsenian$158$136.88 +21.2%Jul 2, 2026
BarclaysAnalyst unavailable$139$136.88 +6.6%Jul 2, 2026
JefferiesAnalyst unavailable$147$136.88 +12.7%Jul 2, 2026
BMO CapitalAnalyst unavailable$174$137.49 +33.5%Jul 1, 2026
JefferiesAnalyst unavailable$157$143.36 +20.4%Jun 23, 2026
Evercore ISIAnalyst unavailable$175$167.96 +34.2%Apr 10, 2026
BarclaysAnalyst unavailable$170$167.96 +30.4%Apr 10, 2026
Deutsche BankAnalyst unavailable$155$167.96 +18.9%Apr 10, 2026
See 88 more

Track every rating change on STZ the moment it posts. Free to start.

Start free

Market reaction

event-close to next-session close
Stock move -1.6% Event window
SPY move -0.1% Same window
Abnormal move -1.5% Stock minus SPY
Volume 1.9× Versus trailing sessions
Subsequent drift -4.7% Up to 20 sessions
STZSPY benchmark

Follow STZ with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

EPS of $3.43 beat consensus of $3.22 by 6.5%; revenue of $2.43B exceeded estimates by 1.9%. Beer gross margins reached 39%, helped by 30bps of fixed-cost overabsorption and 20bps of pricing/mix, partially offset by 30bps of FX headwinds. Operating margins declined 10bps as SG&A rose from Veracruz staffing and marketing spend increased for World Cup support. Management raised full-year marketing spend expectations, with marketing exceeding 10% of net sales in Q2 and Q3. Corona non-alcoholic reached #4 in its category with strong double-digit growth, identified as a white-space opportunity. Jack Edwards, former Diageo beer executive, was hired as new Head of Sales to close distribution and awareness gaps.

Guidance delta

FY27 guidance was maintained despite the Q1 beat. Management explicitly cited limited macro visibility — gas prices spiked over 50% during the quarter — and the dynamic consumer environment, particularly within Hispanic ZIP codes, as reasons not to raise the outlook after one strong quarter. Prior quarter analysis noted that FY27 beer margin guidance had been lowered to 37-38% due to Veracruz fixed-cost absorption and higher SG&A; that margin outlook was not revised this quarter.

Key takeaways

  • Beat driven by beer strength: EPS $3.43 vs $3.22 est (+6.5%), revenue $2.43B vs $2.39B est (+1.9%).
  • Guidance maintained — management cited macro uncertainty and gas-price-driven consumer volatility as reasons not to raise FY27 outlook after one beat.
  • Marketing spend stepped up materially — over 10% of net sales in Q2/Q3, targeting World Cup, college football, and NFL.
  • Corona non-alcoholic is a genuine white-space win — #4 in category with strong double-digit growth; management sees room to invest further.
  • Veracruz brewery remains on track for mid-fiscal-year commissioning, but pre-launch staffing is pressuring SG&A until it goes live.
  • Market reaction was negative — stock fell 1.45% on the event and drifted down an additional 4.75% subsequently, with volume 1.86x baseline.

Management priorities

  • Accelerate marketing investment in Q2/Q3 around World Cup, college football, and NFL to drive brand saliency and consumer occasions.
  • Commission the Veracruz brewery mid-fiscal year to unlock fixed-cost absorption and shift SG&A into COGS.
  • Close distribution and awareness gaps for Modelo Especial and core brands through new sales leadership.
  • Scale Corona non-alcoholic and explore additional white-space opportunities using test-and-learn capabilities.
  • Maintain cost-savings discipline to support gross margins amid rising SG&A and marketing spend.
  • Deploy differentiated playbooks for established brands (saliency and relevance) versus emerging brands (distribution and awareness building).

Sources

  1. Earnings call transcript and parsed analysis · 2026-07-02T00:05:35.673721+00:00
  2. FN2 earnings calendar · 2026-07-30T01:23:13.872335+00:00
  3. Polygon adjusted daily market bars · 2026-07-31T00:11:49.221454+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T00:11:49.218742+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.